Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 24, 2024 09:00 ET | Source: ProLynx LLC

ProLynx announces a publication proposing that a long-acting prodrug of SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors

SAN FRANCISCO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc., a biotech company with a unique technology for tunable half-life extension of drugs, announced publication of a paper entitled “Could...
April 13, 2020 09:00 ET | Source: ProLynx LLC

ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38) with the PARP inhibitor Rubraca® (rucaparib) at the National Cancer Institute

SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- ProLynx LLC today announced that the first patient was treated with its PLX038 in a Phase 1B clinical trial for small-cell lung cancer at the...